NEW YORK – Clinical research organization ProSciento announced Thursday a partnership with biomarker technology firm Nordic Bioscience to identify translational biomarkers for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).